MOTS-c in Rodent Models of Obesity and Diabetes: Adipose Tissue, Liver, Pancreatic Islets and the Diabetic Heart

RESEARCH · MOTS-C · OBESITY & DIABETES MODELS

MOTS-c in Rodent Models of Obesity and Diabetes: Adipose Tissue, Liver, Pancreatic Islets and the Diabetic Heart

PurixLab’s MOTS-C 10mg is a research vial of the 16-amino-acid mitochondrial-derived peptide first described in 2015. Our earlier articles cover the overall research picture, the exercise and AMPK signalling work in muscle and circulating levels in humans. This article moves to the organs outside skeletal muscle that rodent models of obesity and diabetes have examined: adipose tissue, the liver, pancreatic islets and the diabetic heart, with attention to how each model was built and what it can and cannot show. The material is supplied for laboratory research use only, and nothing here describes effects of any PurixLab product.

The starting point: diet-induced obesity in mice

The founding study reported that MOTS-c treatment in mice prevented age-dependent and high-fat-diet-induced insulin resistance, as well as diet-induced obesity, with skeletal muscle appearing to be the primary target organ [1]. A 2019 follow-up used untargeted plasma metabolomics in diet-induced obese mice and found three pathways reduced in treated animals: sphingolipid, monoacylglycerol and dicarboxylate metabolism, all of which the authors note are upregulated in obese and type 2 diabetic models. They linked the effect to improved insulin sensitivity and increased beta-oxidation that prevented fat accumulation, including fatty liver [2]. Plasma metabolite panels of this kind are one of the few readouts that could, in principle, be compared across species.

Adipose tissue: browning and thermogenesis

Fat has emerged as a second target. In a cold-exposure model, serum MOTS-c fell after cold stress, and treatment enhanced cold tolerance, reduced lipid trafficking to the liver, upregulated brown adipose thermogenic gene expression and increased white fat browning; inhibiting ERK signalling disturbed the thermogenic effect [3]. In ovariectomised mice, a model of oestrogen loss, a second 2019 study reported prevention of ovariectomy-induced obesity and insulin resistance, increased brown fat activation and less inflammatory infiltration of white adipose tissue, with an AMPK blocker attenuating the effect on adipocyte lipid metabolism [4]. Two different upstream kinases, ERK and AMPK, are therefore proposed for overlapping adipose readouts.

Cell work adds a mitochondrial-dynamics angle. In mammalian cells, MOTS-c raised markers of mitochondrial biogenesis yet reduced the mitochondrial count, alongside increases in the fusion GTPases OPA1 and MFN2; blocking them with TNF-alpha or knocking down MFN2 abrogated MOTS-c-induced GLUT4 translocation and glucose uptake [5]. Regulation of endogenous MOTS-c also connects fat and muscle: in adiponectin-knockout mice, plasma and muscle MOTS-c were downregulated, a high-fat diet lowered MOTS-c in wild-type animals, and adiponectin raised MOTS-c expression in myotubes through an APPL1-SIRT1-PGC-1alpha pathway [6].

The liver: steatohepatitis and fibrosis

Liver studies are more recent. In a diet-induced model of nonalcoholic steatohepatitis, both long-term preventive and short-term therapeutic protocols alleviated steatosis, apoptosis, inflammation and fibrosis and reversed a mitochondrial metabolic deficiency. The authors identified a direct interaction between MOTS-c and the BH3 domain of the anti-apoptotic protein Bcl-2, which stabilised Bcl-2 and suppressed its ubiquitination; a Bcl-2 inhibitor or virus-mediated Bcl-2 knockdown removed the benefit [7]. In a type 2 diabetic rat model with liver fibrosis, MOTS-c, aerobic exercise or both improved fibrosis, and cell experiments implicated the Keap1-Nrf2 and TGF-beta1/Smad pathways [8]. Bcl-2 binding and Keap1-Nrf2 signalling are not obviously the same mechanism, which is a recurring feature of this literature.

Pancreatic islets: autoimmunity and senescence

Islet work has used two distinct models. In non-obese diabetic (NOD) mice, MOTS-c ameliorated hyperglycaemia and reduced islet-infiltrating immune cells, and T cells transferred from treated NOD mice lowered diabetes incidence in immunodeficient recipients; the effect was attributed to TCR/mTORC1 signalling in T cells, and patients with type 1 diabetes had lower serum MOTS-c than controls [9]. A 2025 study led by the same first author reported that MOTS-c levels decrease with ageing and senescence in islet cells, that treatment reduced senescence in aged mouse islets and improved glucose intolerance in S961-treated and NOD mice, and that circulating levels were lower in type 2 diabetes [10]. In a gestational diabetes model built from a short high-fat diet plus low-level streptozotocin, MOTS-c alleviated hyperglycaemia and insulin resistance, reduced birth weight and offspring death, and protected beta cells from streptozotocin injury [11].

The diabetic heart

Cardiac studies mostly use rats given a high-fat diet with low-level streptozotocin. In that model, MOTS-c lowered fasting glucose and C-reactive protein and reduced NLRP3, ASC and cleaved caspase-1 in left ventricular tissue [12]; a separate group reported reduced ROS/TXNIP/NLRP3 pathway proteins after 8 weeks of treatment [13]. Respirometry in the same kind of model found that untreated diabetic hearts had lower oxygen flux at oxidative phosphorylation, and that treatment for 3 weeks lowered fasting glucose and cardiac hypertrophy while increasing OXPHOS respiration [14]. In streptozotocin-induced type 1 diabetic mice, 12 weeks of treatment by osmotic pump ameliorated cardiac dysfunction, dilatation and adverse remodelling, with restored AMPK signalling [15].

A result that points the other way

Not every model is favourable. In adipose-derived mesenchymal stromal cells from people with obesity, exogenous MOTS-c restored intracellular levels and activated AMPK but reduced proliferation, increased the senescence genes p16 and p21 and upregulated TNF-alpha. In a mouse renal artery stenosis model, pretreated cells failed to improve renal perfusion or fibrosis, and pretreatment also blunted the reparative effect of lean-donor cells [16]. The authors describe a dissociation between metabolic activation and functional stemness, a reminder that AMPK activation is not a proxy for benefit in every cell type.

Reading these models critically

Several caveats apply across the set. Most studies are from a small number of laboratories and use one species, one sex or one induction protocol. Streptozotocin models combine beta-cell toxicity with diet, so they are not equivalent to human type 2 diabetes. Proposed mediators differ between organs (AMPK, ERK, Bcl-2, Keap1-Nrf2, mTORC1), and few papers test them against one another. Outcomes are largely histology, gene expression and glucose tolerance rather than long-term function.

What remains open

  • Mechanism by organ. Different targets have been proposed for fat, liver and islets [3,7,9].
  • Model dependence. Several cardiac studies rely on high-fat diet plus streptozotocin [12,14].
  • Endogenous regulation. Diet and adiponectin both change endogenous MOTS-c levels [6].
  • Contrary findings. In obese-donor stromal cells, MOTS-c increased senescence markers [16].

MOTS-C 10mg at PurixLab

MOTS-C 10mg: a labelled lyophilized research vial with 10mg per vial, C$54 per vial (CAD, before tax), supplied for laboratory research only. Batch documentation is available on request. Product page: purixlab.com/product/mots-c-10mg/.

PurixLab ships within Canada only, from stock held in Toronto. Standard shipping is C$15, and shipping is free when the product subtotal is C$200 or more after discounts. Orders outside the GTA ship by Canada Post Xpresspost. Prices are in CAD and taxes are calculated from your shipping address at checkout.

In Toronto and the GTA, our own team delivers orders the same day or the next day. There is no fixed GTA delivery fee: after you place your order, we email you to confirm the delivery time and any delivery charge, and then you pay. There is no storefront or local pickup.

Payment is by Interac e-Transfer (instructions are shown at checkout) or by cryptocurrency through Plisio (Bitcoin, Ethereum, USDT and more): choose Plisio at checkout and you are sent to a secure Plisio payment page after placing the order. Current offers and any pack pricing are shown on the product page and in your cart; offers do not stack.

For laboratory research use only. Not for human or veterinary use, not for consumption, injection or application to skin, and purchasers must be 18 or older. The studies summarised above describe specific materials in published research; they are not claims about any PurixLab product.

View MOTS-C 10mg

Questions or batch documentation requests: [email protected] · Shipping & Delivery · Toronto & GTA delivery · PurixLab FAQ

References

  1. Lee C, Zeng J, Drew BG, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015;21(3):443-54. PubMed 25738459 · PMC4350682 · doi:10.1016/j.cmet.2015.02.009
  2. Kim SJ, Miller B, Mehta HH, et al. The mitochondrial-derived peptide MOTS-c is a regulator of plasma metabolites and enhances insulin sensitivity. Physiol Rep. 2019;7(13):e14171. PubMed 31293078 · PMC6640593 · doi:10.14814/phy2.14171
  3. Lu H, Tang S, Xue C, et al. Mitochondrial-Derived Peptide MOTS-c Increases Adipose Thermogenic Activation to Promote Cold Adaptation. Int J Mol Sci. 2019;20(10):2456. PubMed 31109005 · PMC6567243 · doi:10.3390/ijms20102456
  4. Lu H, Wei M, Zhai Y, et al. MOTS-c peptide regulates adipose homeostasis to prevent ovariectomy-induced metabolic dysfunction. J Mol Med (Berl). 2019;97(4):473-485. PubMed 30725119 · doi:10.1007/s00109-018-01738-w
  5. Bhullar KS, Shang N, Kerek E, et al. Mitofusion is required for MOTS-c induced GLUT4 translocation. Sci Rep. 2021;11(1):14291. PubMed 34253808 · PMC8275580 · doi:10.1038/s41598-021-93735-2
  6. Guo Q, Chang B, Yu QL, et al. Adiponectin treatment improves insulin resistance in mice by regulating the expression of the mitochondrial-derived peptide MOTS-c and its response to exercise via APPL1-SIRT1-PGC-1α. Diabetologia. 2020;63(12):2675-2688. PubMed 32880686 · doi:10.1007/s00125-020-05269-3
  7. Lu H, Fan L, Zhang W, et al. The mitochondrial genome-encoded peptide MOTS-c interacts with Bcl-2 to alleviate nonalcoholic steatohepatitis progression. Cell Rep. 2024;43(1):113587. PubMed 38206815 · doi:10.1016/j.celrep.2023.113587
  8. Chen F, Li Z, Wang T, et al. MOTS-c mimics exercise to combat diabetic liver fibrosis by targeting Keap1-Nrf2-Smad2/3. Sci Rep. 2025;15(1):18460. PubMed 40425777 · PMC12116857 · doi:10.1038/s41598-025-03526-2
  9. Kong BS, Min SH, Lee C, et al. Mitochondrial-encoded MOTS-c prevents pancreatic islet destruction in autoimmune diabetes. Cell Rep. 2021;36(4):109447. PubMed 34320351 · PMC10083145 · doi:10.1016/j.celrep.2021.109447
  10. Kong BS, Lee H, L'Yi S, et al. Mitochondrial-encoded peptide MOTS-c prevents pancreatic islet cell senescence to delay diabetes. Exp Mol Med. 2025;57(8):1861-1877. PubMed 40855115 · PMC12411631 · doi:10.1038/s12276-025-01521-1
  11. Yin Y, Pan Y, He J, et al. The mitochondrial-derived peptide MOTS-c relieves hyperglycemia and insulin resistance in gestational diabetes mellitus. Pharmacol Res. 2022;175:105987. PubMed 34798268 · doi:10.1016/j.phrs.2021.105987
  12. Mills AR, de Souza A, Pham T, et al. Mitochondrial peptide MOTS-c suppresses systemic and cardiac inflammasome activation in a diabetic rat model. Exp Physiol. 2026;111(8):3742-3752. PubMed 42321010 · PMC13394035 · doi:10.1113/EP093714
  13. Fu Y, Tang M, Duan Y, et al. MOTS-c regulates the ROS/TXNIP/NLRP3 pathway to alleviate diabetic cardiomyopathy. Biochem Biophys Res Commun. 2024;741:151072. PubMed 39616938 · doi:10.1016/j.bbrc.2024.151072
  14. Pham T, Taberner A, Hickey A, et al. Mitochondria-derived peptide MOTS-c restores mitochondrial respiration in type 2 diabetic heart. Front Physiol. 2025;16:1602271. PubMed 40661667 · PMC12257629 · doi:10.3389/fphys.2025.1602271
  15. Wu N, Shen C, Wang J, et al. MOTS-c Peptide Attenuated Diabetic Cardiomyopathy in STZ-Induced Type 1 Diabetic Mouse Model. Cardiovasc Drugs Ther. 2025;39(3):491-498. PubMed 38141139 · doi:10.1007/s10557-023-07540-2
  16. Xing L, Lu B, Zhu X, et al. Mitochondrial-derived peptide MOTS-c activates metabolic signaling but blunts reparative function in human mesenchymal stromal cells. Inflamm Regen. 2026;46(1):35. PubMed 42324588 · PMC13536784 · doi:10.1186/s41232-026-00431-7

Leave a Comment

Your email address will not be published. Required fields are marked *